13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002106939
Total reported value
$187.9M
$187.9M
85 檔
38.6%
At the close of Q4 2025, PSP Research LLC disclosed equity holdings valued at approximately $187.9M, spread across 85 reported holdings.
During Q4 2025, PSP Research LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including SGOV, PRAX, TVTX) accounted for 38.6% of total reported equity market value during Q4 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SGOV | Ishares 0-3 Month Treasury B | ETF-Gov Bonds | 61.41% | -12.35% | — | |
| 2 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.51% | -0.34% | EXIT | |
| 3 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.51% | — | — | |
| 4 | TYRA | Tyra Biosciences Inc | Stock-Other | 0.50% | -0.43% | EXIT | |
| 5 | PHVS | Pharvaris N.V. | Stock-Other | 0.50% | -0.12% | — | |
| 6 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 0.48% | +0.12% | NEW | |
| 7 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.48% | -0.03% | — | |
| 8 | CGON | Cg Oncology Inc | Stock-Other | 0.48% | — | — | |
| 9 | BLTE | Belite Bio Inc - Adr | Stock-Other | 0.48% | — | — | |
| 10 | ASND | Ascendis Pharma A/S | Stock-Other | 0.48% | -0.40% | EXIT | |
| 11 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 0.48% | — | — | |
| 12 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.48% | — | — | |
| 13 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.48% | +0.12% | NEW | |
| 14 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.48% | — | — | |
| 15 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.48% | -0.20% | — | |
| 16 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.48% | +0.01% | — | |
| 17 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 0.48% | -0.06% | — | |
| 18 | KOD | Kodiak Sciences Inc | Stock-Other | 0.47% | -0.15% | — | |
| 19 | IMNM | Immunome Inc | Stock-Other | 0.47% | -0.11% | — | |
| 20 | AUPH | Aurinia Pharmaceuticals Inc | Stock-Other | 0.47% | -0.04% | — | |
| 21 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 0.47% | -0.17% | — | |
| 22 | HALO | Halozyme Therapeutics Inc | Stock-Healthcare | 0.47% | -0.08% | — | |
| 23 | EYPT | Eyepoint Inc | Stock-Other | 0.47% | -0.01% | — | |
| 24 | ALKS | Alkermes plc | Stock-Healthcare | 0.47% | +0.02% | — | |
| 25 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.47% | -0.07% | — | |
| 26 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.47% | — | — | |
| 27 | ACLXGBX | Arcellx Inc | Stock-Other | 0.47% | — | — | |
| 28 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 0.47% | -0.03% | — | |
| 29 | ZYME | Zymeworks Inc | Stock-Other | 0.47% | -0.04% | — | |
| 30 | SUPN | Supernus Pharmaceuticals Inc | Stock-Healthcare | 0.47% | -0.07% | — | |
| 31 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.47% | -0.02% | — | |
| 32 | HRMY | Harmony Biosciences Holdings | Stock-Other | 0.47% | -0.09% | — | |
| 33 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.47% | — | — | |
| 34 | RPRX | Royalty Pharma plc | Stock-Healthcare | 0.47% | -0.04% | — | |
| 35 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 0.47% | -0.01% | — | |
| 36 | LQDA | Liquidia CORP | Stock-Other | 0.47% | +0.21% | NEW | |
| 37 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.47% | -0.12% | — | |
| 38 | PVLA | Palvella Therapeutics Inc | Stock-Other | 0.47% | — | — | |
| 39 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.46% | — | — | |
| 40 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 0.46% | -0.02% | — | |
| 41 | INSM | Insmed Inc | Stock-Healthcare | 0.46% | — | — | |
| 42 | LEGN | Legend Biotech Corp-adr | Stock-Other | 0.46% | -0.15% | EXIT | |
| 43 | ARGX | Argenx Se - Adr | Stock-Healthcare | 0.46% | -0.01% | — | |
| 44 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.46% | -0.09% | — | |
| 45 | NUVL | Nuvalent Inc-a | Stock-Other | 0.46% | — | — | |
| 46 | INCY | Incyte CORP | Stock-Healthcare | 0.46% | -0.03% | — | |
| 47 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.46% | -0.39% | EXIT | |
| 48 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.46% | — | — | |
| 49 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 0.46% | -0.04% | — | |
| 50 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.46% | — | — |
According to official SEC Form 13F filings, PSP Research LLC reported a total U.S. public equity portfolio value of $187.9M across 85 disclosed positions in Q4 2025.
During Q4 2025, PSP Research LLC's top holdings by market value included SGOV (61.4%)、PRAX (0.5%)、TVTX (0.5%). The largest single position, SGOV, represented 61.4% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q4 2025, PSP Research LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.